Extended Data Fig. 6: CSF tau biomarker changes by APOE4 genotype. | Nature Aging

Extended Data Fig. 6: CSF tau biomarker changes by APOE4 genotype.

From: ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Extended Data Fig. 6

Both APOE4- and APOE4 + AADvac1-treated patients contribute to the difference from placebo. Error bars denote mean change and 95% CI of mean. FAS, patients with both baseline and end-of-study values (placebo n = 7, all APOE4 positive; AADvac1 APOE4 positive n = 10, APOE4 negative n = 10 for pT181 and total tau, and n = 9 for pT217 tau).

Source data

Back to article page